Transition from subcutaneous levodopa/carbidopa (ND0612) to Foslevodopa/Foscarbidopa in advanced Parkinson's disease Authors: Matteo Alessandro De Rosa, Dario Calisi, Mirella Russo, Astrid Thomas, Stefano Luca Sensi Published: 2026 ABSTRACT Background: Continuous subcutaneous levodopa infusion is an established option for advanced Parkinson's disease (PD). Subcutaneous levodopa/carbidopa infusion (ND0612) and foslevodopa/foscarbidopa (ABBV-951) are available infusion systems; however, no clinical guidance exists regarding conversion between these treatments.Methods: We report two patients with advanced PD receiving ND0612 in combination with oral levodopa who underwent complete transition to ABBV-951. Initial foslevodopa/foscarbidopa dosing was estimated according to levodopa equivalent daily dose and subsequently titrated under close neurological supervision. Motor fluctuations, non-motor symptoms, quality of life, and infusion-site tolerability were evaluated at baseline and at 3-month follow-up using standardized clinical assessments.Results: Both transitions were completed within one day without acute adverse events. At three months, both patients showed a marked reduction in daily off time, improvement in dyskinesias and freezing of gait, and stabilization of sleep and behavioral symptoms. ABBV-951 demonstrated improved local tolerability, with no infusion-site complications observed during follow-up.Conclusions: Conversion from ND0612 to ABBV-951 appears feasible, and safe in advanced PD. These preliminary observations may provide practical insight in the absence of published data addressing this specific therapeutic transition. Parkinson's disease (PD) is characterized by progressive motor and non-motor complications and increasing variability in response to oral dopaminergic therapy as the disease advances [1]. In advanced stages, oral treatments often lose efficacy, leading to unpredictable motor fluctuations, delayed n responses, on-off phenomena, disabling nocturnal symptoms, and worsening of non-motor manifestations. Continuous dopaminergic stimulation delivered through infusion therapies has therefore become an established therapeutic strategy for patients with advanced PD inadequately controlled with oral regimens [2], [3]. ND0612 is a continuous subcutaneous levodopa–carbidopa infusion system that has demonstrated the ability to stabilize plasma levodopa concentrations in phase III clinical trials (NCT04006210) [4], [5], [6], [7]. However, it requires a combination with oral levodopa/carbidopa, as it is not suitable for monotherapy. Foslevodopa/foscarbidopa (ABBV-951) is a recently approved subcutaneous formulation delivering a soluble levodopa prodrug with more favorable pharmacokinetic properties, including higher bioavailability and reduced plasma variability, and can be used as monotherapy [8], [9], [10], [11]. Despite the growing availability of these systems, no standardized clinical guidance exists for transitioning patients between different subcutaneous levodopa infusion therapies. Here, we report the first real-world experience of two patients with advanced PD who underwent conversion from ND0612 to ABBV-951. We focus on the clinical feasibility, safety, motor and non-motor outcomes, and tolerability of the switch, supported by standardized assessments, video documentation, and a 3-month follow-up. Methods Case description – patient one The first patient was a 79-year-old man with a 15-year history of PD, who was initiated on ND0612 in 2019 within a clinical trial. His medical history included hypertension, dyslipidemia, and benign prostatic hyperplasia. He was under an ND0612 regimen with a total daily levodopa dose (LEDD) of 720 mg, with early satisfactory motor control. However, approximately two years after ND0612 initiation, and with notable worsening in recent months, the patient developed severe motor fluctuations, including afternoon and evening akinesia, unpredictable on-off phenomena, delayed on responses, and painful foot dystonia during off periods. Freezing of gait (FoG) emerged, resulting in falls approximately once per week. Notably, no significant dyskinesias were reported throughout this period. Neuropsychiatric symptoms included apathy, irritability, verbal aggression (especially during on phases), delusions, impulse control disorders (binge eating, compulsive shopping), and hallucinations. The latter were effectively controlled with quetiapine 50 mg daily. Other non-motor symptoms included nocturia, urinary incontinence, insomnia, REM-sleep behavior disorder (RBD), and mild dysphagia for liquids. A diagnosis of major neurocognitive disorder with moderate executive dysfunction was established (see Supplementary Material - Table 1), and treatment with rivastigmine transdermal patch (4.6 mg daily) and clonazepam (10 drops at night) was initiated. Before the switch, according to the trial protocol (ClinicalTrials.gov NCT02726386), a total dose of ND0612 up to 12 mL daily (LEDD = 720 mg) was administered using the CRONO TWIN ND infusion pump system via 2 infusion sites. The pump system was programmed to deliver an infusion rate of 0.08 mL/h for 6 h from 22:00–04:00 (night rate), with an automatic change to 0.64 mL/h for 18 h from 04:00–22:00 (day rate). Concomitant oral therapy included levodopa/carbidopa (250/25 mg once daily, 100/25 mg t.i.d.), levodopa/benserazide extended-release 100/25 mg at bedtime, and safinamide 100 mg daily, resulting in a total LEDD of 1345 mg (720 mg from ND0612 + 625 mg from oral therapy) plus safinamide 100 mg/day. Case description – patient two Patient Two was a 74-year-old man with a 14-year history of PD who started ND0612 infusion therapy in 2022 as part of a clinical trial. His medical history included prior ischemic stroke, hypertension, carotid atherosclerosis, and benign prostatic hyperplasia. The infusion regimen was 720 mg daily and provided initially satisfactory motor control. However, over the years, the patient developed progressive motor fluctuations, and in recent months he experienced early-morning, postprandial, evening, and nocturnal akinesia, accompanied by painful nocturnal myalgias. He also had persistent daily peak-dose dyskinesia, lasting on average 4.5 h per day, occasionally troublesome. Both the patient and his caregiver reported increasing difficulty managing infusion sites due to multiple subcutaneous nodules and fibrotic skin changes. Neuropsychiatric symptoms included irritability, hallucinations, and apathy. Other non-motor symptoms included nocturia, RBD, and constipation. Neuropsychological evaluation revealed mild cognitive impairment with executive dysfunction (see Supplementary Material - Table 2), treated with rivastigmine transdermal patch (4.6 mg daily). He was also prescribed clonazepam (8 drops at night) to mitigate the RBD. ND0612 was delivered using the same two-site infusion protocol as patient one. Oral therapy included levodopa/carbidopa 100/25 mg twice daily, melevodopa/carbidopa 25/100 mg once daily, and safinamide 100 mg daily, for a total LEDD of 1020 mg (720 mg from ND0612 + 300 mg from oral therapy) plus safinamide. Switch from ND0612 to ABBV-951 A complete switch to ABBV-951 was performed in both patients, with discontinuation of ND0612 and all oral levodopa formulations within a single day. Given the absence of conversion guidance and the pharmacokinetic differences between active levodopa infusion and prodrug delivery, a conservative, individualized titration strategy was adopted, with daily neurological evaluations over three consecutive days. Initial ABBV-951 dosing was estimated from the previous LEDD and subsequently adjusted based on clinical response. ABBV-951 infusion allowed flexible programming with distinct low (night), basal (daytime), and high (as-needed) rates. Regimens were subsequently optimized and reassessed during the following week and at 1- and 3-month follow-up. Final individualized infusion regimens achieved from Day 2 and at 3-month follow-up are reported in Table 1.Table 1ABBV-951 infusion parameters after titration.Individualized ABBV-951 infusion settings for two patients at Day 2 and at 3-month follow-up, including loading dose, extra dose, low, basal and high infusion rates, total Levodopa Equivalent Daily Dose (LEDD), and concomitant therapy. Total LEDD was calculated assuming a nocturnal low-rate infusion for 7 h and a daytime basal-rate infusion for the remaining 15 h. The high-rate infusion was used on an as-needed basis and was not included as part of the daily continuous regimen. Infusion settings were individualized according to clinical response.Patient 1 –Day 2Patient 1 –3 monthsPatient 2 –Day 2Patient 2 –3 monthsLoading dose (mL)1.21.21.21.2Extra dose (mL)0.300.300.300.30Low rate (22:00–07:00) mL/h0.270.290.260.26Basal rate (07:00–22:00) mL/h0.340.350.280.29High rate (if needed) mL/h0.360.370.300.30Total LEDD (mg/day)13451336.210201137.3Concomitant therapySafinamide 100 mgSafinamide 100 mgSafinamide 100 mgSafinamide 100 mg Table 1ABBV-951 infusion parameters after titration.Individualized ABBV-951 infusion settings for two patients at Day 2 and at 3-month follow-up, including loading dose, extra dose, low, basal and high infusion rates, total Levodopa Equivalent Daily Dose (LEDD), and concomitant therapy. Total LEDD was calculated assuming a nocturnal low-rate infusion for 7 h and a daytime basal-rate infusion for the remaining 15 h. The high-rate infusion was used on an as-needed basis and was not included as part of the daily continuous regimen. Infusion settings were individualized according to clinical response.Patient 1 –Day 2Patient 1 –3 monthsPatient 2 –Day 2Patient 2 –3 monthsLoading dose (mL)1.21.21.21.2Extra dose (mL)0.300.300.300.30Low rate (22:00–07:00) mL/h0.270.290.260.26Basal rate (07:00–22:00) mL/h0.340.350.280.29High rate (if needed) mL/h0.360.370.300.30Total LEDD (mg/day)13451336.210201137.3Concomitant therapySafinamide 100 mgSafinamide 100 mgSafinamide 100 mgSafinamide 100 mg ABBV-951 infusion parameters after titration. Individualized ABBV-951 infusion settings for two patients at Day 2 and at 3-month follow-up, including loading dose, extra dose, low, basal and high infusion rates, total Levodopa Equivalent Daily Dose (LEDD), and concomitant therapy. Total LEDD was calculated assuming a nocturnal low-rate infusion for 7 h and a daytime basal-rate infusion for the remaining 15 h. The high-rate infusion was used on an as-needed basis and was not included as part of the daily continuous regimen. Infusion settings were individualized according to clinical response. Multiple standardized motor evaluations were performed on both patients receiving ND0612 and oral medication, ND0612 without oral medication, after the initiation of ABBV-951, and at 3 months after ABBV-951. These repeated evaluations enabled a rigorous within-subject comparison, minimizing confounding variables and clearly isolating the effect of the new infusion therapy. Results In both patients, the transition from ND0612 to ABBV-951 was completed within one day and was well tolerated, with no acute adverse events or clinically relevant worsening during the titration phase. Clinical outcomes are summarized in Table 2; at 3-month follow-up, motor response remained stable with minimal need for dose adjustments.Table 2Clinical outcomes before and after transition from ND0612 to ABBV-951.Comparison of motor severity, motor complications, non-motor symptoms, sleep quality, and health-related quality of life at three different clinical states: on oral therapy + on ND0612; off oral therapy + on ND0612; and off oral therapy + on ABBV-951 at 3-month follow-up.Patient 1Patient 2Med on - ND0612 onMed off - ND0612 onMed off - ABBV-951 on (3-months FU)Med on - ND0612 onMed off - ND0612 onMed off -ABBV-951 on(3-months FU)MDS-UPDRS - part III317928286416MDS-UPDRS - part IV13-59-2mHY3432.542.5Off-time5 h-1.5 h4 h-1On-time with slight dyskinesia1.5 h-04.5 h-0PDQ-39 (raw score)102-4265-23NMSS (raw score)92-2642-12PDSS-2 (raw score)26-1011-2Abbreviations: Movement Disorders Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS), part III and IV; modified Hoehn and Yahr Scale (mHY); Parkinson's Disease Questionnaire-39 (PDQ-39); Non-Motor Symptoms Scale (NMSS); Parkinson's Disease Sleep Scale-2 (PDSS-2); FU (follow-up). Table 2Clinical outcomes before and after transition from ND0612 to ABBV-951.Comparison of motor severity, motor complications, non-motor symptoms, sleep quality, and health-related quality of life at three different clinical states: on oral therapy + on ND0612; off oral therapy + on ND0612; and off oral therapy + on ABBV-951 at 3-month follow-up.Patient 1Patient 2Med on - ND0612 onMed off - ND0612 onMed off - ABBV-951 on (3-months FU)Med on - ND0612 onMed off - ND0612 onMed off -ABBV-951 on(3-months FU)MDS-UPDRS - part III317928286416MDS-UPDRS - part IV13-59-2mHY3432.542.5Off-time5 h-1.5 h4 h-1On-time with slight dyskinesia1.5 h-04.5 h-0PDQ-39 (raw score)102-4265-23NMSS (raw score)92-2642-12PDSS-2 (raw score)26-1011-2Abbreviations: Movement Disorders Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS), part III and IV; modified Hoehn and Yahr Scale (mHY); Parkinson's Disease Questionnaire-39 (PDQ-39); Non-Motor Symptoms Scale (NMSS); Parkinson's Disease Sleep Scale-2 (PDSS-2); FU (follow-up). Clinical outcomes before and after transition from ND0612 to ABBV-951. Comparison of motor severity, motor complications, non-motor symptoms, sleep quality, and health-related quality of life at three different clinical states: on oral therapy + on ND0612; off oral therapy + on ND0612; and off oral therapy + on ABBV-951 at 3-month follow-up. Patient 1Patient 2Med on - ND0612 onMed off - ND0612 onMed off - ABBV-951 on (3-months FU)Med on - ND0612 onMed off - ND0612 onMed off -ABBV-951 on(3-months FU)MDS-UPDRS - part III317928286416MDS-UPDRS - part IV13-59-2mHY3432.542.5Off-time5 h-1.5 h4 h-1On-time with slight dyskinesia1.5 h-04.5 h-0PDQ-39 (raw score)102-4265-23NMSS (raw score)92-2642-12PDSS-2 (raw score)26-1011-2 Patient 1Patient 2Med on - ND0612 onMed off - ND0612 onMed off - ABBV-951 on (3-months FU)Med on - ND0612 onMed off - ND0612 onMed off -ABBV-951 on(3-months FU)MDS-UPDRS - part III317928286416MDS-UPDRS - part IV13-59-2mHY3432.542.5Off-time5 h-1.5 h4 h-1On-time with slight dyskinesia1.5 h-04.5 h-0PDQ-39 (raw score)102-4265-23NMSS (raw score)92-2642-12PDSS-2 (raw score)26-1011-2 Abbreviations: Movement Disorders Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS), part III and IV; modified Hoehn and Yahr Scale (mHY); Parkinson's Disease Questionnaire-39 (PDQ-39); Non-Motor Symptoms Scale (NMSS); Parkinson's Disease Sleep Scale-2 (PDSS-2); FU (follow-up). In patient one, daily off time decreased from approximately 5 h to 1.5 h, with a marked improvement in gait and posture. Freezing of gait became rare and no longer disabling, likely reflecting the absence of prolonged off periods. Dyskinesias remained absent throughout the observation period. Motor benefits were sustained at follow-up and confirmed by standardized clinical examination and video-based assessment. In patient two, daily off time decreased from approximately 4 h to 1 h per day. Peak-dose dyskinesias, previously present for several hours daily, completely resolved after the switch. Motor performance, already partially satisfactory with ND0612, showed further stabilization, particularly during early morning, post-prandial, and nocturnal periods. In both cases, non-motor symptoms improved substantially. Behavioral disturbances and neuropsychiatric symptoms diminished, with regression of impulse control disorders and reduced irritability. Sleep-related symptoms, including nocturnal akinesia and sleep fragmentation, improved consistently, in parallel with the introduction of a stable overnight low-dose infusion rate. These changes were reported by both patients and caregivers and corroborated by clinical follow-up. ABBV-951 might have superior local tolerability compared with ND0612. No infusion-site nodules, pain, erythema, or skin irritation were observed during follow-up. The single-site infusion system, which was replaced every 48–72 h, was perceived as easier to manage and significantly less burdensome than the daily dual-site replacement required with ND0612. Both patients and caregivers reported high satisfaction with device handling and the overall simplicity of treatment. Total LEDD remained stable in patient one and showed a modest increase in patient two, without associated adverse effects. Discussion This report describes the first real-world experience of switching patients with advanced Parkinson's disease from ND0612 to ABBV-951. Our observations indicate that this transition is feasible and safe when performed under close neurological supervision with individualized titration. The switch was associated with changes in motor performance, particularly regarding “off” time and nocturnal symptoms, as well as modifications in non-motor and behavioral manifestations. These effects are likely related to achieving more stable 24-h dopaminergic stimulation and to complete withdrawal of oral levodopa. These findings are consistent with current pathophysiological models suggesting that hallucinations and behavioral disturbances in Parkinson's disease are, at least in part, promoted by pulsatile striatal dopaminergic stimulation, particularly associated with intermittent oral levodopa administration [12]. Continuous dopaminergic delivery, by providing a more physiological and stable receptor stimulation, may therefore mitigate the development and expression of neuropsychiatric complications. In addition, the possibility to independently modulate daytime and nighttime infusion rates emerged as a key advantage in addressing both motor and non-motor fluctuations. Notably, the transition was extremely rapid: within a single day, the optimal dose was achieved and remained largely stable for at least three months. This contrasts with the prolonged titration periods typically required when switching from oral levodopa to infusion therapies, which often extend over several weeks. A plausible explanation is that both patients were already receiving continuous subcutaneous levodopa infusion and were therefore adapted to this pharmacokinetic and pharmacodynamic profile. Equally important, ABBV-951 was associated with favorable tolerability and ease of use in both patients. The single-site infusion system, which requires less frequent site changes and is associated with fewer local complications, may contribute to treatment manageability and long-term adherence in patients requiring continuous dopaminergic delivery. This is particularly relevant, given that infusion-site complications are a leading cause of discontinuation of ND0612 and other subcutaneous therapies [8], [9]. Although limited by the small sample size and observational design, these findings suggest that ABBV-951 may represent a therapeutic option for patients previously treated with ND0612, especially in the presence of nocturnal symptoms, behavioral complications, infusion-site intolerance, or treatment discontinuation due to drug availability. Larger prospective studies are needed to confirm these results and to define evidence-based strategies for switching between subcutaneous levodopa infusion therapies. Funding Sources and Conflicts of Interest This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors declare that Matteo Alessandro De Rosa and Astrid Thoms are Sub-Investigators/Raters - Clinical Study ND0612–317 NeuroDerm. Ethical Compliance Statement The authors confirm that the approval of an institutional review board was not required for this work. The authors confirm that patients' consent was obtained for this work. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. CRediT authorship contribution statement Matteo Alessandro De Rosa: Writing – original draft, Supervision, Formal analysis, Conceptualization. Dario Calisi: Writing – review & editing, Data curation. Mirella Russo: Writing – review & editing, Data curation. Astrid Thomas: Writing – review & editing, Validation, Supervision. Stefano Luca Sensi: Writing – review & editing, Supervision, Formal analysis, Conceptualization. Declaration of competing interest All the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.